CILcare has the capability to customize a full preclinical program in line with your IND approach and project milestones, including GLP Auditory Safety and non-GLP Efficacy studies, for your cochlear molecular therapies.
Gene and Cell Therapies
About 60% of sensorineural hearing loss can be attributed to genetic factors. So far, we know that over 400 genes are linked to some form of hearing loss.
New gene therapy programs are addressing the need for cell specificity for the treatment of both genetic and acquired hearing loss.
The challenge in the field of gene and cell-based therapies is to assess the efficacy and safety of these solutions. The safety of gene or cell therapy programs is assessed in the CILcare/ CBSET Laboratories, in a regulated GLP (Good Laboratory Practice) environment.